ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Hospital Universitario de Jaén
Jaén, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de Jaén (5)
2021
-
Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project
European Journal of Surgical Oncology, Vol. 47, Núm. 2, pp. 276-284
2017
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
2006
-
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer
International Journal of Radiation Oncology Biology Physics, Vol. 66, Núm. 1, pp. 201-205